Synergistic interactions of MmpL3 inhibitors with antitubercular compounds in vitro

Wei Li, Andrea Sanchez-Hidalgo, Victoria Jones, Vinicius Calado Nogueira De Moura, E. Jeffrey North, Mary Jackson

Research output: Contribution to journalArticlepeer-review

42 Scopus citations


A number of inhibitors of the essential Mycobacterium tuberculosis mycolic acid transporter, MmpL3, are currently under development as potential novel antituberculosis agents. Using the checkerboard method to study the interaction profiles of various antituberculosis drugs or experimental compounds with two different chemotypes inhibiting this transporter (indolcarboxamides and adamantyl ureas), we showed that MmpL3 inhibitors act synergistically with rifampin, bedaquiline, clofazimine, and β-lactams.

Original languageEnglish (US)
Article numbere02399
JournalAntimicrobial agents and chemotherapy
Issue number4
StatePublished - Apr 1 2017

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'Synergistic interactions of MmpL3 inhibitors with antitubercular compounds in vitro'. Together they form a unique fingerprint.

Cite this